Quorum Review, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Quorum Review, Inc. - overview
Established
1992
Location
Seattle, WA, US
Primary Industry
Business Support Services
About
Quorum Review, Inc. is a clinical research company specializing in Institutional Review Board (IRB) services, ensuring compliance and protection for human subjects in various clinical trials across North America and select international markets. Founded in 1992 in Seattle, US, Quorum Review, Inc. provides regulatory oversight through its Institutional Review Board (IRB) services.
The company was acquired by Advarra in February 2019, which is a part of a larger portfolio held by American Capital, Linden, and Northlane Capital Partners. There are no records of significant pivots in business strategy or the existence of any subsidiaries. Quorum Review, Inc. offers comprehensive review services through its Institutional Review Board (IRB), focusing on robust human subject protections and compliance in clinical research.
They provide regulatory oversight for multisite studies, including full board and expedited reviews tailored for minimal risk studies. Their proprietary platform, the Advarra Center for IRB Intelligence (CIRBI), enhances communication and review processes for clients, which include academic medical centers, hospitals, and research institutions across North America, Canada, and selected international markets, including cross-border studies. The revenue of Quorum Review, Inc. is primarily generated through a B2B model for its IRB review services.
Clients engage under various transaction structures, including service agreements for full board and expedited reviews based on their specific research needs. The pricing model includes fees for protocol submissions and informed consent documents, with additional charges for rush services. Quorum Review maintains a client-centric support model, ensuring timely delivery of services without extra costs for standard requests, fostering long-term partnerships with research entities. Following its acquisition in February 2019, Quorum Review, Inc.
plans to leverage new resources to enhance its service offerings and expand into new geographic markets. The company is focused on developing innovative products to streamline the IRB review process and aims to penetrate additional international markets by 2025. The recent acquisition funding is expected to support these initiatives, allowing for improvements in technology and service scalability.
Current Investors
Advarra, Inc.
Primary Industry
Business Support Services
Sub Industries
Consulting Services, BPO Services, Pharmaceutical Research & Development
Website
www.quorumreview.com
Company Stage
Add-on
Total Amount Raised
Subscriber access only
Quorum Review, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on | Completed | Quorum Review, Inc. | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.